Analyst Reiterates Buy on Nuvation Bio, Maintains $17 Price Target on Long-Term IBTROZI Growth Potential

Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating on Nuvation Bio and keeping the price target at $17.00.

Robert Burns has given his Buy rating due to a combination of factors that underscore Nuvation Bio’s growth prospects and financial strength. Despite IBTROZI’s first-quarter sales coming in below expectations, he highlights that a large portion of new patients were treatment‑naïve, a segment that historically shows much longer response durations and progression‑free survival, which supports the potential for durable, recurring revenue.

Burns also points to Nuvation’s substantial cash position, which he believes provides a clear runway to profitability and flexibility to expand the pipeline through potential asset purchases. He expects revenue to build as IBTROZI penetration increases, aided by company initiatives to boost molecular testing in community settings and by its inclusion in key treatment guidelines for ROS1‑positive lung cancer patients with brain metastases. On this basis, his discounted cash flow analysis supports maintaining a $17 price target and reiterating a Buy rating.